Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CeriBell, Inc. (Nasdaq: CBLL) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a medical technology company focused on point-of-care electroencephalography (EEG) for serious neurological conditions, CeriBell uses its filings to report financial performance, material agreements, intellectual property actions, and key product milestones related to the Ceribell System.
Investors can review periodic reports and current reports on Form 8-K that describe quarterly financial results, including separate disclosure of product revenue and subscription revenue, as well as updates on cash, marketable securities, and operating expenses. Filings also cover material definitive agreements, such as the Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University for patent rights related to portable brain wave devices, and the Corporate Supply Agreement with Shenzhen Everwin Precision Technology Co., Ltd. and affiliates for EEG headband supply and related licenses.
Other 8-K filings document regulatory and legal developments, including announcements of FDA 510(k) clearance for the Clarity® algorithm in neonatal seizure detection, clearance for the company’s delirium monitoring solution, and the FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor. Filings also describe patent infringement complaints filed against Natus Medical Incorporated and related subsidiaries, as well as lease amendments for office space in Sunnyvale, California and governance changes such as the election of new directors.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand financial trends, material contracts, regulatory events, and intellectual property issues affecting CBLL. Users can also track insider-related disclosures when available through forms such as Form 4, and refer to annual reports on Form 10-K and quarterly reports on Form 10-Q for deeper insight into CeriBell’s business, risk factors, and operations.
Ceribell, Inc. President and CEO Xingjuan Chao exercised stock options and sold shares in a planned series of trades. She exercised options covering 1,446 and 23,554 shares of common stock at an exercise price of $4.70 per share, then sold a total of 39,000 common shares in open-market transactions on March 3, 2026 at weighted average prices around $17.45–$17.46 per share under a Rule 10b5-1 trading plan. Following these transactions, she holds 711,164 shares directly and has indirect exposure to 369,088 additional shares held by the ACP 2021 Trust, where she is a co-trustee and disclaims beneficial ownership beyond her pecuniary interest.
Ceribell, Inc. Chief Technology Officer Raymond Woo reported a set of option exercises and related share sales in Ceribell stock. On March 2, 2026, he exercised multiple stock options to acquire common shares and then sold 11,112 shares of common stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025. The reported sale prices were based on weighted-average prices within ranges from $18.10 to $18.41 per share. After these transactions, Woo directly held 166,912 shares of Ceribell common stock.
CBLL reports Form 144 notice of affiliate sales. The filing lists multiple sales by Xingjuan Chao, including 25,000 shares on 12/04/2025 for 470,532.50, 79,000 shares on 01/05/2026 for 1,680,124.43, 39,000 shares on 02/04/2026 for 786,392.36, and 2,084 shares on 02/23/2026 for 41,251.74.
The form also lists planned option-related sales and grants with dates and share counts, including 9,821 shares (09/25/2024), 4,179 shares (05/15/2025), and 25,000 shares (03/03/2026).
CBLL filed a Rule 144 resale notice listing 4,560 shares of common stock to be sold on 03/03/2026. The filing also lists recent officer sales by David J. Foehr, including 5,265 shares on 12/03/2025 for $88,609.95, 5,556 shares on 01/05/2026 for $125,565.60, 5,556 shares on 02/03/2026 for $111,120.00, 569 shares on 02/23/2026 for $11,263.07, and 781 shares on 02/24/2026 for $15,604.38.
Rebecca B. Robertson reported sales of common stock on a Form 144. The record shows a sale of 5,000 shares on 12/08/2025 for $100,000 and a sale of 2,500 shares on 01/02/2026 for $54,725.
The filing also lists 827 shares associated with restricted stock vesting on 03/01/2026 and shows Fidelity Brokerage Services LLC as a broker of record.
Raymond Woo filed a Form 144 reporting proposed and recent sales of Common stock. The notice lists proposed sales of 9,640 and 1,472 shares dated 03/02/2026, and reports recent sales of 11,112 shares on 01/02/2026, 11,112 shares on 02/02/2026, and 705 shares on 02/23/2026. The entries include cash amounts tied to those past sales.
Ceribell, Inc. senior vice president of finance David Foehr sold 1,350 shares of common stock in open-market transactions. The sales involved 781 shares at an average price of $19.98 on February 24, 2026 and 569 shares at $19.79 on February 23, 2026.
According to the disclosure, these shares were sold to cover tax withholding obligations tied to vesting restricted stock units, and were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. After these sales, Foehr directly owned 17,550 common shares.
Ceribell, Inc. Chief Revenue Officer Joseph S. Manni reported an open-market sale of 768 shares of common stock on February 23, 2026 at $19.79 per share. According to the notes, these shares were sold to cover tax withholding obligations from vesting restricted stock units. After this transaction, he directly owned 26,933 shares, which includes 300 shares acquired under the company’s Employee Stock Purchase Plan on January 30, 2026.
Ceribell, Inc. Chief Technology Officer Raymond Woo reported an open-market sale of 705 shares of common stock at $19.79 per share. According to the disclosure, the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units. After this transaction, Woo directly holds 166,912 shares of Ceribell common stock.
Ceribell, Inc. Chief Financial Officer Scott Blumberg reported an open-market sale of 808 shares of common stock on February 23, 2026 at a price of $19.79 per share. The sale was made to cover tax withholding obligations related to vesting restricted stock units. Following this transaction, he directly holds 118,334 shares, which includes 300 shares acquired under Ceribell's Employee Stock Purchase Plan on January 30, 2026.